Ann: Full year revenue guidance FY23, page-2

FY23 Revenue Guidance

● Biome records unaudited ~$7.23m FY23 sales revenue, up 75% vs. FY22
● Biome records unaudited ~$2m Q4 FY23 sales annualising at $8m

Microbiome health company Biome Australia Limited (ASX: BIO) (‘Biome’ or ‘the
company’) is pleased to announce unaudited full year sales revenue of ~$7.23 million
and Q4 unaudited sales revenue of ~$2 million.

These results represent an annual growth of 75% compared to FY22 audited sales
revenue and an annualised run rate of $8m based on Q4 FY23.

Biome Australia’s Managing Director and Founder, Blair Norfolk commented:
“I am delighted to share the significant sales revenue growth of Biome Australia for
financial year 2023, up 75% vs financial year ‘22. Particularly encouraging are the
quarter four results, with Biome reaching $2m for the quarter, our best quarter to
date. The strong end to the year points toward continued growth into financial year
2024, supported by business development in our existing distribution network and
the launch of several new targeted probiotics in the first half of financial year 2024.”